Prelude Therapeutics Incorporated

NASDAQ (USD): Prelude Therapeutics Incorporated (PRLD)

Last Price

1.02

Today's Change

-0.01 (0.97%)

Day's Change

0.999 - 1.06

Trading Volume

135,090

Overview

Market Cap

56 Million

Shares Outstanding

55 Million

Avg Volume

498,095

Avg Price (50 Days)

1.10

Avg Price (200 Days)

3.28

PE Ratio

-0.58

EPS

-1.77

Earnings Announcement

13-Feb-2025

Previous Close

1.03

Open

1.03

Day's Range

0.999 - 1.0667

Year Range

0.797 - 6.8

Trading Volume

135,090

Price Change Highlight

1 Day Change

-0.97%

5 Day Change

-9.73%

1 Month Change

27.50%

3 Month Change

-47.42%

6 Month Change

-77.63%

Ytd Change

-18.40%

1 Year Change

-70.61%

3 Year Change

-89.29%

5 Year Change

-96.11%

10 Year Change

-96.11%

Max Change

-96.11%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment